Science
Targeting anti-PD1 resistance to transform cancer immunotherapy
Stimulation of the immune system using anti PD-1 antibodies, known as checkpoint therapy, significantly improves survival in some cancers, e.g. melanoma and NSCLC. However, most tumor types don’t respond to checkpoint therapy, with a best case single agent response rate of between 20% and 40%. Activating the immune system can stimulate tumor neoantigens and the priming of T cells, turning “cold” tumors “hot”. Highlight believes BO-112 has a unique ability to modify tumor-intrinsic pathways and the immune system to make tumors more sensitive to IO therapies. BO-112 in combination with anti-PD1 antibodies has shown potent & durable clinical responses in patients not responding to anti-PD1 antibodies.
Turning cold tumors hot
BO-112 in combination with anti-PD1 antibodies shows potent & durable clinical responses in patients not responding to anti-PD1 antibodies.
Infographic: Fundamentium
Optimised immune response - BO-112 multi-pathway approach has a duel positive effect
BO-112 multi-pathway approach has a duel positive effect. Targeting different dsRNA sensors confers superiority to achieve potent immune modulation of tumor micro-environment.
Multi-pathway approach combines activation of immune system to improve effectiveness with direct effect on tumors to make them more sensitive to T-Cell recognition and attack.
Unlocking a large potential oncology market opportunity
BO-112 addressing Primary and Acquired immunity.
